BD200 / Biolojic Design - LARVOL DELTA

This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer. (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Biolojic Design Ltd.

First-in-human • New P1 trial • Oncology • Solid Tumor

The multibody drug conjugate (MDC) BD200 mediates anti-tumor activity through a novel dual-targeting mode (AACR 2026) - "The preclinical data suggest that a bivalent MDC addresses the challenge of tumor heterogeneity, while retaining the developability and the functional traits of a natural, simple, symmetrical human IgG. This may allow BD200 to drive deeper responses in more tumor types and more patients than existing ADCs."

Oncology • NECTIN4

Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting (GlobeNewswire) - "BD200 demonstrated strong anti-tumor responses across patient derived xenografts of triple negative breast cancer, bladder, cervical and esophageal cancer, as well as gastric cancer in cell line-derived xenograft models. BD200 showed strong activity in tumor models derived from patients that were resistant to other ADCs....In cell lines resistant to ADCs that bind only to Nectin-4, switching to BD200 restored potent anti-tumor activity....BD200 is expected to enter clinical trials in the second half of 2026."

New trial • Preclinical • Bladder Cancer • Breast Cancer • Cervical Cancer • Esophageal Cancer • Gastric Cancer